Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof-of-concept study of roflumilast in mild cognitive impairment
2019-004959-36Phase 2Completed
- Sponsor
- ZonMw
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing Roflumilast with Placebo (2 arms). Primary endpoints: Verbal Learning Test immediate recall and Verbal Learning Test delayed recall. Started Sep 2020; status: completed.
02
Drugs
roflumilast
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2019-004959-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004959-36.